A phase II study, ALTA, evaluated the efficacy of two different doses of brigatinib in ALK-positive metastatic NSCLC patients who had experienced disease progression on or intolerance to crizotinib. The gene discussed is ALK; the disease is non-small cell lung carcinoma.